479353-63-4

Usage

Uses

Used in Pharmaceutical Industry:
4-(4-Carboxybenzyl)piperazine-1-carboxylic acid tert-butyl ester is used as a building block in the synthesis of potential pharmaceutical drugs for its versatile chemical reactivity and structural features that can be tailored for specific therapeutic targets.
Used as a Neurotransmitter Modulator:
In medicinal chemistry research, 4-(4-CARBOXYBENZYL)PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER is utilized as a neurotransmitter modulator, leveraging its chemical properties to interact with and potentially influence neurotransmitter systems, which is crucial for the development of drugs targeting neurological disorders.
Used in Anticancer Research:
4-(4-Carboxybenzyl)piperazine-1-carboxylic acid tert-butyl ester has been investigated for its potential anti-cancer properties, indicating its use in cancer research and drug development, where it may contribute to the discovery of novel therapeutic agents against various types of cancer.
Used in Chemical Reagent Development:
4-(4-CARBOXYBENZYL)PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER also serves as a key intermediate in the development of certain chemical reagents, highlighting its importance in the broader field of chemical synthesis and the creation of new, specialized reagents for various applications.
Used in Organic Synthesis:
As an intermediate in organic synthesis, 4-(4-Carboxybenzyl)piperazine-1-carboxylic acid tert-butyl ester is instrumental in the preparation of complex organic molecules, which can be vital for both research and commercial applications in the chemical and pharmaceutical sectors.

InChI:InChI=1/C17H24N2O4/c1-17(2,3)23-16(22)19-10-8-18(9-11-19)12-13-4-6-14(7-5-13)15(20)21/h4-7H,8-12H2,1-3H3,(H,20,21)

Upstream product

• 1642-81-5 p-(chloromethyl)benzoic acid 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 844891-11-8 tert-butyl 4-[(4-methoxycarbonylphenyl)methyl]piperazine-1-carboxylate 
• 1571-08-0 methyl 4-formylbenzoate 

Downstream Products

• 404844-02-6 N-Desmethyl Imatinib 
• 1076199-23-9 tert-butyl 4-(4-((4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)carbamoyl)benzyl)piperazine-1-carboxylate 
• 1344034-11-2 tert-butyl 4-(4-(2-(2-(propylamino)pyridin-4-yl)-1H-benzo[d]imidazol-4-ylcarbamoyl)benzyl)piperazine-1-carboxylate 
• 1344034-06-5 tert-butyl 4-(4-(2-(2-chloropyridin-4-yl)-1H-benzo[d]imidazol-4-ylcarbamoyl)benzyl)piperazine-1-carboxylate 
• 1414935-22-0 4-[4-(4-carbamoyl-2-pyridin-4-yl-thiazol-5-ylcarbamoyl)-benzyl]-piperazine-1-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

Synthesis, in vitro and in vivo evaluation of 18F-fluoronorimatinib as radiotracer for Imatinib-sensitive gastrointestinal stromal tumors

Introduction Gastrointestinal stromal tumors (GIST) have a wide range of mutations, but can mostly be treated with Imatinib, until eventually resistance towards this tyrosine kinase inhibitor is acquired. Early and non-invasive determination of the sensitivity of the tumor and its metastases towards Imatinib by positron emission tomography (PET) would be beneficial for therapy planning and monitoring. Methods We developed a synthesis strategy towards the precursor molecule, performed the 18F-synthesis and in the following evaluated the radioligand in vitro regarding its lipophilicity, stability and biological activity (KIT binding properties) as well as its in vivo properties in GIST tumor-bearing mice. Results [18F]fluoronorimatinib could be obtained in an overall radiochemical yield of 22.2 ± 3.3% within 90 min. The radioligand showed high GIST cell uptake and was able to distinguish between Imatinib-sensitive and resistant tumor cell lines (GIST-T1, GIST882, GIST430) in vitro. Further biological evaluations of the ligand towards 9 different GIST-relevant KIT mutations showed comparable binding affinities compared to the structural lead Norimatinib (65 nM vs. 53 nM for wt-KIT). The in vivo evaluation of the newly developed radioligand showed tumor-to-background-ratios comparable to previously described, similar radiotracers. Conclusions Thus, [18F]fluoronorimatinib is able to distinguish between Imatinib-resistant and sensitive KIT mutations. Although no improvement of in vivo tumor-to-background ratios could be achieved compared to formerly described radioligands, the hepatic uptake could be considerably reduced, being advantageous for the imaging of GIST. Advances in knowledge and implications for patient care: We were able to show that it is possible to significantly reduce the unfavorably high hepatic uptake of small-molecule radioligands applicable for GIST PET imaging. This work can thus be the basis for further work intending to develop a PET-radioligand for Imatinib-dependent GIST imaging.

COMPOSITIONS AND METHODS FOR INHIBITING KINASES

The present invention provides methods for the prevention or treatment of Parkinson's Disease using Abelson-family tyrosine kinase inhibitors.

COMPOSITIONS AND METHODS FOR INHIBITING KINASES

The present invention provides compounds for the prevention or treatment of cancer or a bacterial or viral infection. Additionally, the present invention provides compositions and methods for using these compounds and compositions in the prevention or treatment of cancer or a bacterial or viral infection in a subject.